Top Stories
Cloud breach exposed proprietary information as the drugmaker launches an investigation.
The company is now anticipating revenues of $67.6 billion this year, an increase of $300 million from its prior projection.
Late-stage vaccine misses interim statistical benchmark as biotech trims R&D outlook and awaits key FDA decision on its mRNA flu shot.
The series C financing will go toward its lead Actinium-225 programme, pipeline expansion and manufacturing scale-up.
The miss in the Phase III ZEUS study sent the company's shares down more than 10%.
Conference News
HANGZHOU, China, July 31, 2026 /PRNewswire/ -- CellOrigin, a biotechnology company focused on next-generation in vivo and in vitro cell therapy technologies, has announced two major progresses in both...
Novel, fast-acting, non-scheduled peptide analgesic addresses the military priority for effective, non-addictive battlefield pain controlKISSIMMEE, Fla.--(BUSINESS WIRE)--PVP Labs, a clinical-stage bi...
The Ask Us Europe survey, led by an academic team in London, and supported by ViiV Healthcare, found 81% of respondents living with HIV recalled having a treatment review, but only 45% had discussed l...
Brazil seeks validation of the elimination of mother-to-child transmission of hepatitis B - PAHO/WHO | Pan American Health Organization ...
Superiority data from LATA, together with OPERA findings, add to the clinical and real-world evidence base for long-acting injectable CabenuvaSix-month follow-up CLARITY data further reinforce a more ...
